17.85  0.35 (2%)		10-23 16:00
Open: 17.76 High: 17.85 Volume: 47,076		Pre. Close: 17.5 Low: 17.74 Market Cap: 110(M)

Short term
Mid term
Targets	6-month :	21.97	1-year :	22.92
Resists	First :	18.81	Second :	19.62
Pivot price	18.28
Supports	First :	17.5	Second :	14.56
MAs	MA(5) :	17.85	MA(20) :	18.47
	MA(100) :	17.54	MA(250) :	17.61
MACD	MACD :	-0.3	Signal :	-0.2
%K %D	K(14,3) :	13.4	D(3) :	16.4
RSI	RSI(14): 43.5
52-week	High :	19.62	Low :	14.38

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ KURE ] has closed above bottom band by 31.7%. Bollinger Bands are 26.1% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	17.85 - 17.94	17.94 - 18.03
Low:	17.53 - 17.62	17.62 - 17.72
Close:	17.69 - 17.84	17.84 - 17.99

This exchange-traded fund will allocate at least 80% of its net assets, including any capital acquired through borrowing for investment purposes, to financial instruments that are components of its underlying index or exhibit similar economic characteristics. The reference index is a market capitalization-weighted measure, adjusted for free float, and applies a 10/40 Constraint. Its objective is to gauge the equity market performance of Chinese enterprises within the healthcare sector. This fund does not maintain a diversified portfolio.

Fri, 23 Oct 2026
Understanding Momentum Shifts in (KURE) - Stock Traders Daily

Thu, 22 Oct 2026
Healthcare ETF: China May Control A Key Bottleneck In AI Drug Discovery - Seeking Alpha

Wed, 21 Oct 2026
Healthcare ETF: China May Control a Key Bottleneck in AI Drug Discovery - KraneShares

Mon, 28 Sep 2026
MRNA Stock Eyes Best Year Ever: Analyst Calls China’s AI Drug Lead ‘Baseless’ As Moderna Awaits Cancer Data - TradingView

Fri, 18 Sep 2026
Healthcare ETF: Treatment Breakthroughs Make China A Medical Destination - KraneShares

Mon, 15 Jun 2026
Healthcare ETF: Outbound Biotech Licensing As Potential New Growth Driver In China - KraneShares

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Neutral
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Neutral
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Neutral
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Neutral
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange: AMEX
Sector: Financial Services
Industry: Asset Management - Global
Shares Out	0 (M)
Shares Float	0 (M)
Held by Insiders	0 (%)
Held by Institutions	0 (%)
Shares Short	0 (K)
Shares Short P.Month	0 (K)

EPS	0
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	0 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	0 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	0 (M)

PE Ratio	0
PEG Ratio	0
Price to Book value	0
Price to Sales	0
Price to Cash Flow	0

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.